# Addressing Cognitive Fog in Long-COVID-19 Patients

> **NCT05597722** · PHASE4 · TERMINATED · sponsor: **Eva Szigethy** · enrollment: 7 (actual)

## Conditions studied

- Cognitive Impairment
- Long COVID

## Interventions

- **BEHAVIORAL:** Digital cognitive behavioral intervention-RxWell
- **DRUG:** Amphetamine-Dextroamphetamine

## Key facts

- **NCT ID:** NCT05597722
- **Lead sponsor:** Eva Szigethy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-04
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to the evolving nature of COVID-related cognitive fog, it was determined that the study would be terminated at this time. The team agreed that it isn't feasible to collect enough data to evaluate the efficacy of the treatments.
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597722, "Addressing Cognitive Fog in Long-COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05597722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*